Pressmeddelande -
Breakthrough for Corline’s 1.5 MEUR unique Regenerative Medicine Project - receives Funding from the European Commission
Swedish biotech company Corline Systems AB, a maker and distributor of CHS which is a unique and proprietary heparin coating technology for use on medical devices and for Regenerative Medicine, today announced that a consortium led by Corline has received a substantial grant from the European Commission to further develop the CHS technology for use in Regenerative Medicine.
“We are very proud to have been chosen by the European Commission in this commercialization programme, and to me the grant signals at least two things: first that Corline has a truly unique technology base and commercialization plan, and also that the Regenerative Medicine industry as such is rapidly evolving from pre-clinical phase to market launch. The coming 2 years will involve a significant step forward in developing our offering to the Regenerative Medicine industry, and I feel we have a compelling proposition in a very exciting industry space”, concludes CEO Henrik Nittmar.
The total contribution by the European Commission is 1.14 MEUR and Corline’s application was selected among more than 600 competing projects.
“This is a fantastic opportunity for Corline. The EU will render us substantial financial support for developing key commercial applications, and our technology is recognized and stands out in a very competitive landscape”, comments CEO Henrik Nittmar.
The funding is granted under the EU FP7 programme ‘Research for the benefit of the SME’. It supports a consortium consisting of 11 partners who will be working on 4 different Regenerative Medicine projects, all of which use Corline’s CHS technology to improve products destined for clinical use. The project will run during 24 months and involves a mix of pre-clinical and clinical evaluations of innovative products within cell therapy and tissue engineering. In addition to being a technology supplier to all projects, Corline will also be running a cell therapy project in the Diabetes Type 1 area.
Ämnen
- Företagande, allmänt
Kategorier
- tissue engineering
- islet transplantation
- corline heparin surface
- cell transplantation
- diabetesvård
- cellterapi
- regenerative medicine
- uppsala
- innovation
- sme
- life science
About Corline and CHS
Corline is a biotechnology company based in Uppsala, Sweden, that develops, manufactures and distributes a proprietary patent protected heparin conjugate surface (CHS) that can be used both for medical devices and for Regenerative Medicine (cell therapy and tissue engineering). In 2008 the market for Regenerative Medicine totaled a 1.5 bn USD turnover, with a 90 % share being focused in the US. The US based market analysis company Life Science Intelligence, estimates the total potential to be over 100 bn USD.
CHS can be used to coat living cells and tissue without compromising their biological functions. CHS helps attenuate the local inflammation that is formed on and around grafts at transplantation, and promotes new blood vessels to grow more quickly to support the graft. For the patient, CHS potentially means better clinical outcome and a more rapid recovery from treatment.
Corline conducts pre-clinical and clinical studies within a number of cell and tissue therapy areas. These studies are a first step towards realizing the company’s vision of having its CHS platform technology widely used within the future Regenerative Medicine market. The CHS technology is protected by more than 20 granted and pending patents.
Corline is a privately held company, financially backed by members of the Crafoord family, primarily known for the development of Swedish medical device company Gambro (founded by Holger Crafoord), and Lars Sunnanväder, a well-known entrepreneur who has founded several medical device and biotechnology companies, e.g. heart/lung assist and coronary surgical device manufacturer Jostra, lung assist device manufacturer Novalung, Jotec, Jolife, Joline and other companies within this field.
For more information, please contact:
Henrik Nittmar, CEO
Tel. +46 (0)18 71 30 90
henrik.nittmar@corline.se
